A mostrar 1 - 9 resultados de 9 para a pesquisa 'Gerd A. Kullak-Ublick', tempo de pesquisa: 0.03seg Refinar resultados
  1. 1
    Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase™ from 2010 to 2020

    Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase™ from 2010 to 2020 Por Imke Ortland, Mahtabalsadat Mirjalili, Gerd A. Kullak-Ublick, Payam Peymani

    Publicado em 2021-05-01
    Obter o texto integral
    Artigo
  2. 2
    Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years

    Pharmacovigilance in ophthalmology in Switzerland: an analysis of the most frequently reported ocular adverse drug reactions within the last 25 years Por Julia E. Karrer, Luis Giovannoni, Gerd A. Kullak-Ublick, Stefan Weiler

    Publicado em 2019-06-01
    Obter o texto integral
    Artigo
  3. 3
    The Impact of PPARγ Genetic Variants on IBD Susceptibility and IBD Disease Course

    The Impact of PPARγ Genetic Variants on IBD Susceptibility and IBD Disease Course Por Jessica Mwinyi, Christa Grete-Wenger, Jyrki J. Eloranta, Gerd A. Kullak-Ublick

    Publicado em 2012-01-01
    Obter o texto integral
    Artigo
  4. 4
    Severe injection site reactions after subcutaneous administration of Sayana®: a retrospective, post-marketing analysis of WHO and Swiss spontaneous pharmacovigilance reports

    Severe injection site reactions after subcutaneous administration of Sayana®: a retrospective, post-marketing analysis of WHO and Swiss spontaneous pharmacovigilance reports Por Annika Jödicke, Hendrike Dahmke, Beat Damke, Martina Schäublin, Gerd A. Kullak-Ublick, Stefan Weiler

    Publicado em 2017-05-01
    Obter o texto integral
    Artigo
  5. 5
    Rescue Therapy for Supratherapeutic Concentrations of Calcineurin Inhibitors Using Potent Cytochrome P450 Inducers

    Rescue Therapy for Supratherapeutic Concentrations of Calcineurin Inhibitors Using Potent Cytochrome P450 Inducers Por Seth Duwor, Katharina Enthofer, Christoph Ganter, Prabin Poudel, Anna Svarin, Gerd A. Kullak-Ublick

    Publicado em 2024-01-01
    Obter o texto integral
    Artigo
  6. 6
    Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Outcome Study Compared With Matched Retrospective Data

    Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Ou... Por Andreas Trojan, Christian Kühne, Michael Kiessling, Johannes Schumacher, Stefan Dröse, Christian Singer, Christian Jackisch, Christoph Thomssen, Gerd A Kullak-Ublick

    Publicado em 2024-05-01
    Obter o texto integral
    Artigo
  7. 7
    L-carnitine co-administration prevents colistin-induced mitochondrial permeability transition and reduces the risk of acute kidney injury in mice

    L-carnitine co-administration prevents colistin-induced mitochondrial permeability transition and reduces the risk of acute kidney injury in mice Por Sophia L. Samodelov, Zhibo Gai, Francesca De Luca, Klara Haldimann, Sven N. Hobbie, Daniel Müller, Gerd A. Kullak-Ublick, Michele Visentin

    Publicado em 2024-07-01
    Obter o texto integral
    Artigo
  8. 8
    Drug-related problems and factors influencing acceptance of clinical pharmacologists’ alerts in a large cohort of neurology inpatients

    Drug-related problems and factors influencing acceptance of clinical pharmacologists’ alerts in a large cohort of neurology inpatients Por Anne B Taegtmeyer, Ivanka Curkovic, Natascia Corti, Christoph Rosen, Marco Egbring, Stefan Russmann, Andreas R Gantenbein, Michael Weller, Gerd A Kullak-Ublick

    Publicado em 2012-07-01
    Obter o texto integral
    Artigo
  9. 9
    Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

    Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Ca... Por Andreas Trojan, Sven Roth, Ziad Atassi, Michael Kiessling, Reinhard Zenhaeusern, Yannick Kadvany, Johannes Schumacher, Gerd A Kullak-Ublick, Matti Aapro, Alexandru Eniu

    Publicado em 2024-04-01
    Obter o texto integral
    Artigo

Ferramentas de pesquisa: